Camp4 Therapeutics Corporation
CAMP
$4.36
$0.163.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.82% | -46.63% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.82% | -46.63% | -- | -- | -- |
| Cost of Revenue | 0.14% | -16.40% | -3.57% | 10.16% | 4.17% |
| Gross Profit | 4.54% | 14.29% | 11.76% | 5.78% | 4.64% |
| SG&A Expenses | 10.31% | 1.64% | 20.50% | 27.77% | 21.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.92% | -10.64% | 3.23% | 14.71% | 8.41% |
| Operating Income | 0.22% | 8.96% | 2.66% | -2.89% | -1.75% |
| Income Before Tax | -47.44% | -203.37% | -11.98% | -0.09% | 0.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.44% | -203.37% | -11.98% | -0.09% | 0.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.44% | -203.37% | -11.98% | -0.09% | 0.15% |
| EBIT | 0.22% | 8.96% | 2.66% | -2.89% | -1.75% |
| EBITDA | 1.01% | 8.90% | 2.73% | -2.94% | -1.93% |
| EPS Basic | 48.70% | 2.83% | 97.71% | 97.60% | 97.68% |
| Normalized Basic EPS | 48.70% | 2.83% | 97.79% | 97.60% | 97.68% |
| EPS Diluted | 48.70% | 2.83% | 97.71% | 97.60% | 97.68% |
| Normalized Diluted EPS | 48.70% | 2.83% | 97.79% | 97.60% | 97.68% |
| Average Basic Shares Outstanding | 187.42% | 212.23% | 4,793.20% | 4,068.67% | 4,199.74% |
| Average Diluted Shares Outstanding | 187.42% | 212.23% | 4,793.20% | 4,068.67% | 4,199.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |